ADCT
ADC Therapeutics SA
$1.05
-0.94%
$133.6M
No data for this timeframe.
Vol
Market Cap$133.6M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (92%)
Insider Activity0B / 3S
Insider Net $-$10.0M
SEC Reports5
Recent Activity
Jun 3, 2026
SEC
ADC Therapeutics announced topline results from the Phase 3 LOTIS-5 confirmatory trial of ZYNLONTA (loncastuximab tesiri
8-K — Impact 6/10
Jun 3, 2026
Insider
Squarer Ron surrendered for taxes 15,196 shares
Director @ $3.08 ($46.8K)
Jun 3, 2026
Insider
Coughlin Timothy surrendered for taxes 12,600 shares
Director @ $3.08 ($38.8K)
Jun 3, 2026
Insider
Hug Peter surrendered for taxes 2,156 shares
Director @ $3.08 ($6.6K)
May 8, 2026
short_volume
Short Volume: ADCT — 55.7% short (0.3M / 0.5M)
Short: 292,003 | Exempt: 73,271 | TRF Vol: 524,035 | Short Ratio: 55.7% | Off-exchange volume (dark
May 4, 2026
SEC
ADC Therapeutics reported Q1 2026 product revenue of $20.0M (+15% YoY), in line with consensus, but GAAP net loss per sh
8-K — Impact 4/10
Apr 20, 2026
SEC
ADC Therapeutics SA (ADCT) has filed a definitive proxy statement (DEFA14A) for its upcoming shareholder meeting, which
DEFA14A — Impact 2/10
Price Targets
$5.00
+376.2% upside
Strong Buy
Current $1.05
Low $2.00
Median $3.00
High $10.00
3 analysts
$2.00
$10.00
Analyst Ratings
5Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 8, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy → Neutral |
| Jun 4, 2026 | RBC Capital | DOWNGRADE | Outperform → Sector Perform |
| May 5, 2026 | RBC Capital | REITERATE | Outperform → Outperform |
| May 5, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 23, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.21 ▼ -0.8% | $-0.24 — $-0.19 | 58% YoY | 5 |
| Next Q | $-0.22 ▼ -2.5% | $-0.27 — $-0.19 | 26% YoY | 5 |
| Current FY | $-0.85 | $-0.91 — $-0.78 | 24% YoY | 5 |
| Next FY | $-0.66 ▼ -7.2% | $-0.74 — $-0.57 | 22% YoY | 4 |
Latest Reports
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | Squarer Ron | F | $46.8K |
| Jun 3, 2026 | Coughlin Timothy | F | $38.8K |
| Jun 3, 2026 | Hug Peter | F | $6.6K |
| Jun 3, 2026 | Monges Viviane | F | $8.0K |
| Jun 3, 2026 | Sandor Victor | F | $38.8K |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
8 unique insiders with 17 transactions. Net insider value: -$10.0M ($0.00 bought, $10.0M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Squarer Ron | Director | TAX W/H | 15,196 | $3.08 | $46.8K |
| Jun 3, 2026 | Coughlin Timothy | Director | TAX W/H | 12,600 | $3.08 | $38.8K |
| Jun 3, 2026 | Hug Peter | Director | TAX W/H | 2,156 | $3.08 | $6.6K |
| Jun 3, 2026 | Monges Viviane | Director | TAX W/H | 2,596 | $3.08 | $8.0K |
| Jun 3, 2026 | Sandor Victor | Director | TAX W/H | 12,600 | $3.08 | $38.8K |
| Jun 3, 2026 | BIZZARI JEAN-PIERRE | Director | TAX W/H | 12,600 | $3.08 | $38.8K |
| Jun 3, 2026 | Azelby Robert | Director | TAX W/H | 12,600 | $3.08 | $38.8K |
| Jun 1, 2026 | Sandor Victor | Director | AWARD | 45,000 | — | — |
| Jun 1, 2026 | Azelby Robert | Director | AWARD | 45,000 | — | — |
| Jun 1, 2026 | Coughlin Timothy | Director | AWARD | 45,000 | — | — |
| Jun 1, 2026 | Squarer Ron | Director | AWARD | 45,000 | — | — |
| Jun 1, 2026 | Hug Peter | Director | AWARD | 45,000 | — | — |
| Jun 1, 2026 | BIZZARI JEAN-PIERRE | Director | AWARD | 45,000 | — | — |
| Jun 1, 2026 | Monges Viviane | Director | AWARD | 45,000 | — | — |
| Apr 2, 2026 | Redmile Group, LLC | 10%+ Owner | SELL | 2,634,506 | $3.28 | $8.6M |
| Apr 1, 2026 | Redmile Group, LLC | 10%+ Owner | SELL | 169,265 | $3.80 | $643.0K |
| Mar 31, 2026 | Redmile Group, LLC | 10%+ Owner | SELL | 196,229 | $3.75 | $736.3K |
5 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 1 mixed, 3 neutral. Avg impact: 4.4/10.
MIXED
8-K
6/10
ADC Therapeutics announced topline results from the Phase 3 LOTIS-5 confirmatory trial of ZYNLONTA (
Jun 3, 2026
NEUTRAL
8-K
4/10
ADC Therapeutics reported Q1 2026 product revenue of $20.0M (+15% YoY), in line with consensus, but
May 4, 2026
NEUTRAL
DEFA14A
2/10
ADC Therapeutics SA (ADCT) has filed a definitive proxy statement (DEFA14A) for its upcoming shareho
Apr 20, 2026
NEUTRAL
EFFECT
4/10
ADC Therapeutics SA has announced the effectiveness of a shelf registration (Form S-3) filed with th
Mar 17, 2026
BEARISH
S-3
6/10
ADC Therapeutics filed an S-3 shelf registration, signaling potential future share issuance. The com
Mar 10, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (92% buy). Based on 12 analysts: 5 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$5.00 mean target
+376.2% upside
Strong Buy (1.80)
$2.00 Low
$10.00 High
| Metric | Value |
|---|---|
| Current Price | $1.05 |
| Target Low | $2.00 |
| Target Mean | $5.00 |
| Target Median | $3.00 |
| Target High | $10.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (1.80) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.21 | $-0.24 | $-0.19 | 58.0% | -0.8% | 0↑ 2↓ | $0.0B | 2.8% | 5 |
| Next Q 2026-09-30 |
$-0.22 | $-0.27 | $-0.19 | 26.0% | -2.5% | 0↑ 1↓ | $0.0B | 15.7% | 5 |
| Current FY 2026-12-31 |
$-0.85 | $-0.91 | $-0.78 | 23.8% | -0.5% | 1↑ 1↓ | $0.1B | 0.1% | 5 |
| Next FY 2027-12-31 |
$-0.66 | $-0.74 | $-0.57 | 22.4% | -7.2% | 1↑ 2↓ | $0.1B | 52.3% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.210 | |
| 7d ago | $-0.208 | -0.002 |
| 30d ago | $-0.208 | -0.002 |
| 60d ago | $-0.193 | -0.017 |
| 90d ago | $-0.198 | -0.012 |
2 analyst firms have rated this stock: 0 upgrades, 2 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 8, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Jun 4, 2026 | RBC Capital | DOWNGRADE | Outperform | Sector Perform |
| May 5, 2026 | RBC Capital | REITERATE | Outperform | Outperform |
| May 5, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 23, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 8, 2026
short_volume
Short Volume: ADCT — 55.7% short (0.3M / 0.5M)
Short: 292,003 | Exempt: 73,271 | TRF Vol: 524,035 | Short Ratio: 55.7% | Off-exchange volume (dark pool + OTC)
May 4, 2026
short_volume
Short Volume: ADCT — 55.4% short (0.3M / 0.6M)
Short: 334,841 | Exempt: 26,434 | TRF Vol: 604,821 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
May 4, 2026
earnings_calendar
ADCT Q1 2026 Earnings Scheduled — 2026-05-04
Mar 10, 2026
earnings_calendar
ADCT Q4 2025 Earnings After Market Close — 2026-03-10